oa SA Pharmaceutical Journal - Pulmonary arterial hypertension : an overview for pharmacists : review
Pulmonary arterial hypertension (PAH) is a syndrome characterised by a progressive increase in pulmonary vascular resistance which leads to right ventricular overload and eventually to right ventricular failure and premature death. It is associated with several predisposing factors and causes which play a role in the choice of therapy, as well as the prognosis. The syndrome has recently been reclassified in order to assist with therapy choice. Initial signs and symptoms include unexplained breathlessness and fatigue. Until the identification of three pathological pathways, the prognosis was very poor, but based on these pathways, recent advances in therapy have significantly improved functional scores and symptoms. Early diagnosis and appropriate treatment play a significant role in the management of this syndrome.
Article metrics loading...